key: cord-0928853-c7py2qio
authors: Chen, Qingxing; Xu, Lili; Dai, Yongbin; Ling, Yunlong; Mao, Jiahao; Qian, Juying; Zhu, Wenqing; Di, Wencheng; Ge, Junbo
title: Cardiovascular manifestations in severe and critical patients with COVID‐19
date: 2020-06-20
journal: Clin Cardiol
DOI: 10.1002/clc.23384
sha: 67e3843d0ed75ccd863dc14990f73b226a63f7ba
doc_id: 928853
cord_uid: c7py2qio

BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) could cause virulent infection leading to Corona Virus Disease 2019 (COVID‐19)‐related pneumonia as well as multiple organ injuries. HYPOTHESIS: COVID‐19 infection may result in cardiovascular manifestations leading to worse clinical outcome. METHODS: Fifty four severe and critical patients with confirmed COVID‐19 were enrolled. Risk factors predicting the severity of COVID‐19 were analyzed. RESULTS: Of the 54 patients (56.1 ± 13.5 years old, 66.7% male) with COVID‐19, 39 were diagnosed as severe and 15 as critical cases. The occurrence of diabetes, the level of D‐dimer, inflammatory and cardiac markers in critical cases were significantly higher. Troponin I (TnI) elevation occurred in 42.6% of all the severe and critical patients. Three patients experienced hypotension at admission and were all diagnosed as critical cases consequently. Hypotension was found in one severe case and seven critical cases during hospitalization. Sinus tachycardia is the most common type of arrythmia and was observed in 23 severe patients and all the critical patients. Atrioventricular block and ventricular tachycardia were observed in critical patients at end stage while bradycardia and atrial fibrillation were less common. Mild pericardial effusion was observed in one severe case and five critical cases. Three critical cases suffered new onset of heart failure. Hypotension during treatment, severe myocardial injury and pericardial effusion were independent risk factors predicting the critical status of COVID‐19 infection. CONCLUSION: This study has systemically observed the impact of COVID‐19 on cardiovascular system, including myocardial injury, blood pressure, arrythmia and cardiac function in severe and critical cases. Monitoring of vital signs and cardiac function of COVID‐19 patients and applying potential interventions especially for those with hypotension during treatment, severe myocardial injury or pericardial effusion, is of vital importance.

injuries, cellular immune deficiency and coagulation activation. [2] [3] [4] It is reported that about 12% of patients with COVID-19 suffered cardiac injury. 5 However, cardiovascular manifestations after COVID-19 infection has not been reported systemically. This study was aimed to explore how COVID-19 affects cardiovascular system including myocardium, conduction systems, cardiac function and blood pressure especially in severe and critical cases and to identify potential risk factors predicting the severity of COVID-19.

We collected medical records of 54 patients diagnosed as severe and critical cases admitted to hospital from January 27 to February 28, 2020. All the patients enrolled in this study were diagnosed according to the sixth edition guideline issued by China's National Health Commission. Severe cases were classified when meeting any one of the following: (1) respiratory distress: RR > =30times/ min; (2) fingertip oxygen saturation < =93% under resting state;

(3) arterial partial pressure of oxygen (PaO 2 )/fraction of inspiration O 2 (FiO 2 ) < =300 mmHg (1 mmHg = 0.133 kPa). Critical cases were classified when meeting any one of the following: (1) respiratory failure and an artificial airway required for invasive mechanical ventilation; (2) shock; (3) combining failure of other organs which requires ICU monitoring and treatment. Clinical, laboratory, electrocardiogram (ECG) and echocardiographic data were obtained from electronic medical record system and reviewed by a trained team of cardiologists. This study was approved by the institutional ethics.

Blood pressure and pulse rate were measured at least every 4 hours during hospitalization using automatic blood pressure recording machines. Hypotension was defined as systolic blood pressure <90 mmHg and/or diastolic blood pressure <60 mmHg. Tachycardia was defined as a heart rate >100 beats/minute in at least two consecutive readings. Bradycardia was defined as a daytime heart rate <50 beats/minutes while awake in at least two consecutive readings. The temperature was charted every 4 hours by eardrum thermometers.

Patients were checked for new onset or change of symptoms. Blood tests were performed regularly. Cardiac injury was defined if the serum level of specific cardiac biomarkers (eg, troponin I) was above 99% upper reference limit. Serious cardiac injury was defined if the serum level of troponin I (TnI) was above 3 times upper reference limit. 6 Echocardiography was performed when it was deemed necessary by the physician in charge, such as significant hypotension that necessitated inotropic support or when there were suspicious changes of myocardial ischemia on electrocardiogram. ECG was performed when clinically indicated, such as the occurrence of unexplained or severe tachycardia, bradycardia, or hypotension, or when cardiac arrhythmia was suspected.

Continuous variables were expressed as the means and SDs. Categorical variables were summarized as the counts and percentages in each category. For comparison of non-parametric variables, Pearson χ 2 test was used. Multi-factor logistic regression model was used to analyze the related factors of COVID-19 critical type. A P value <.05 was considered significant.

Among 54 patients enrolled in our study, 39 (72.2%) were diagnosed as severe and 15 (27.8%) as critical cases. Thirty-six (66.7%) patients were males. Gender differences were similar in severe and critical groups. The median age was 57.6 (44.9-70.3, between 25 and 78) years old. Patients over 65 years old occupied almost one third, while the average age was similar in severe and critical groups. Nine patients had a history of cardiocerebrovascular diseases, including six patients with coronary artery disease (four severe and two critical cases), one patient with aortic and mitral valve replacement (severe case), one patient with mild to moderate mitral regurgitation (critical case) and one patient with persistent atrial fibrillation and acute cerebral infarction (critical case). None of the cases studied had a previous history of chronic heart failure or chronic lung disease. The presenting symptoms of fever occurred in 47 (87.0%) patients, including 34 (63.0%) low-grade fever, 9 (16.6%) moderate fever and 4 (7.4%) high fever, respectively. No difference in fever type was observed between severe and critical group. The occurrence of diabetes and the level of D-dimer, white blood cell (WBC), procalcitonin, interleukin-6 (IL-6), erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) in critical cases were significantly higher than severe cases (P < .01), indicating that patients with diabetes and a higher level of D-dimer and inflammation are more susceptible to develop critical conditions. Cardiac biomarkers were remarkedly higher in critical group (P < 0.01), suggesting more serious myocardial injury. Renal function biomarkers were similar in severe and critical cases, while acute kidney injury occurred in about one third of patients in both groups. Clinical features and laboratory findings were summarized in Table 1 .

Four patients (two severe and two critical) complained of chest pain, but none of them were found to have TnI elevation or ECG change.

Presence of chest pain may be due to pleuritis caused by pneumonia.

Elevation of TnI was observed in 23 (42.6%) patients. Notably three patients with highly elevated TnI (>3 times the upper reference limit), indicative of severe myocardial injury, were all critical cases. The serum levels of TnI, CK-MB and myoglobin were significantly higher

Demographic and clinical characteristics in severe and critical patients in critical group compared to severe group (P < .01). In addition, elevation of TnI was consistent with the elevation of inflammatory markers especially procalcitonin and IL-6 (Supporting Information Figure S1 ), indicating the role of inflammation and cytokine storm in cardiac injury. ST-T changes in ECG were identified in four patients (one severe and three critical) and three of them were accompanied by increase of TnI. NT-proBNP elevation occurred in 30 (55.6%) patients.

Eight patients presented with significantly elevated NT-proBNP (>3 times the upper reference limit), including five critical cases. The concentration of NT-proBNP were remarkedly higher in critical group, compared to severe group (P < .01) ( Table 2 ).

Sixteen (29.6%) patients had a history of hypertension in this study. (Table 3) .

Sinus tachycardia is the most common type of arrythmia and was observed in 23 (59.0%) severe patients and all the critical patients (P < .01). It is noteworthy that the rising of heart rate was not consis- 

We performed echocardiography in 31 patients, including 13 severe and 18 critical patients. Occurrence of mild pericardial effusion was observed in one severe case and five critical cases (P < .01),

suggesting critical patients are more likely to develop pericardial effusion. Three critical cases suffered from new onset of heart failure.

Two cases presented with right heart failure, accompanied by right heart enlargement and pulmonary hypertension and unfortunately ended up with death. One case presented with reversible left heart failure and elevation of TnI, indicative of possibility of myocarditis, but it is a pity that we failed to obtain the histopathology. During hospitalization, cardiomegaly was not found in any patient without heart failure (Table 3 ). In our study blood pressure in 56% patients with a history of hypertension were out of control at admission. It may be attributed to increased catecholamine related to stress and anxiety and ACE2 pathway influenced by SARS-CoV-2 infection. 9 It is noteworthy that three patients suffered from hypotension at admission and seven patients suffered from persistent hypotension during hospitalization and all of them developed critical status consequently. Presence of hypotension Echocardiographic data showed occurrence of mild pericardial effusion in about one-third of critical patients without manifestation of heart failure, which might be due to inflammatory effusion. Three critical cases were reported to suffer from new onset of heart failure:

two cases developed right heart failure after "white lung" at end stage of the disease; one case presented with reversible left heart failure and TnI elevation, indicative of occurrence of myocarditis but regrettably lack of pathological evidence. In other patients without heart failure, no impaired diastolic function, abnormal wall motion or cardiomegaly were found, which was inconsistent with previous publication. 10 More detailed studies are needed to get a comprehensive understanding of cardiovascular manifestations and cardiac function change of SARS-CoV-2 infection.

It is the first time to systemically report cardiovascular manifestations after COVID-19 infection, providing some reference for clinical practice. Our results suggested that more attention should be paid to old adult male patients and diabetic patients who are more susceptible to develop critical conditions. The occurrence of cardiac injury in our study is significantly higher than data in previous studies probably due to different severity of enrolled patients, urging us to attach importance to heart protection when choosing optimal treatment strategies especially in managing those severe and critical cases. Hypotension was an independent risk factor for critical status and poor prognosis.

Therefore, blood pressure should be closely monitored during the hospitalization period. Sinus tachycardia was the most common type of arrythmia in patients with COVID-19, especially in severe and critical cases. Ventricular tachycardia and atrioventricular block were less common, but they may act as warning signs for disease deterioration. Close observation of vital signs is advised. Mild pericardial effusion occurred in about one-third of critical patients without manifestation of heart failure and was another independent risk factor for critical disease status. More detailed studies are needed to get a deeper understanding of cardiovascular manifestations of SARS-CoV-2 infection.

Main limitation of this study was small sample size. Only 54 confirmed severe and critical COVID-19 patients from single center were enrolled, making it difficult to get a full understanding of the relation between COVID-19 and cardiovascular system. Besides, the followup data should be collected to get a knowledge of the long-term impact of COVID-19 on cardiovascular system.

This study has systemically reported the impact of COVID-19 on cardiovascular system, including myocardial injury, blood pressure, arrythmia and cardiac function in severe and critical cases. Hypotension during treatment, severe myocardial injury and pericardial effusion were the independent risk factors of critical disease status in patients with COVID-19. Monitoring of vital signs and cardiac function of COVID-19 patients and applying potential interventions especially for those with hypotension during treatment, severe myocardial injury or pericardial effusion, is of vital importance.

World Health Organization. Coronavirus disease 2019 (COVID-19): situation report-60

A novel coronavirus from patients with pneumonia in China

Caution on kidney dysfunctions of 2019-nCoV patients

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Fourth universal definition of myocardial infarction

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China

Analysis of myocardial injury in patients with COVID-19 and association between concomitant cardiovascular diseases and severity of COVID-19

ACE2: from vasopeptidase to SARS virus receptor

SUPPORTING INFORMATION Additional supporting information may be found online in the Supporting Information section at the end of this article. How to cite this article

Cardiovascular manifestations in severe and critical patients with COVID-19

This study was funded by Shanghai Science and Technology Commission (17DZ1930303).

https://orcid.org/0000-0002-9360-7332